Pharmaids Pharma Eyes ₹105 Cr Deal Amid Expansion Push and Strategic Realignment

Pharmaids Pharmaceuticals Ltd is reportedly evaluating a ₹105 million (₹10.5 crore) consideration linked to a potential investment or acquisition, signaling a strategic shift as the company looks to scale operations and diversify its portfolio. While the exact contours of the transaction remain undisclosed, the move aligns with Pharmaids’ recent capital restructuring and asset expansion efforts.

 

Key Highlights:

 

- Deal Under Evaluation: The ₹105 million consideration is believed to be tied to either a strategic acquisition or investment in a complementary pharma or specialty chemicals business. The company has not yet issued a formal announcement detailing the counterparty or structure.

 

- Financial Context:

- Pharmaids reported FY25 revenue of ₹19.4 crore, up from ₹15 crore in FY24.

- However, it posted a net loss of ₹13.5 crore, reflecting continued margin pressures and high operating costs.

- Promoter holding remains low at 5.22%, with public shareholding exceeding 94%.

 

- Growth Strategy:

- The company has been expanding its bulk drug and specialty chemical portfolio, including products like Retinol, Coenzyme Q10, and Vitamin E derivatives.

- It is also investing in hospital care and skincare verticals, with a focus on contract manufacturing.

 

- Market Buzz:

- The stock has gained over 21% in the past year, despite weak fundamentals, driven by speculative interest and restructuring hopes.

- Analysts caution that clarity on the ₹105 million deal will be key to assessing its long-term impact.

 

If confirmed, the deal could mark a turning point for Pharmaids as it seeks to pivot from a loss-making legacy to a leaner, growth-focused future.

 

Source: Screener.in, Moneycontrol, Economic Times